Download PDF
Thromb Haemost 1998; 80(01): 37-41
DOI: 10.1055/s-0037-1615135
Rapid Communication
Schattauer GmbH

Comparison between von Willebrand Factor (VWF) and VWF Antigen II in Normal Individuals and Patients with von Willebrand Disease

Christophe de Romeuf
1   From the Laboratoire de Recherche sur l’Hémostase, Laboratoire Français du Fractionnement et des Biotechnologies, Lille, France
,
Claudine Mazurier
1   From the Laboratoire de Recherche sur l’Hémostase, Laboratoire Français du Fractionnement et des Biotechnologies, Lille, France
› Author Affiliations
Further Information

Publication History

Received 29 July 1997

Accepted after revision 26 February 1998

Publication Date:
08 December 2017 (online)

    Permissions and Reprints

Summary

Von Willebrand disease is characterised by a quantitative (type 1) or qualitative (type 2) decrease in von Willebrand factor (vWF) a multimeric glycoprotein involved in primary haemostasis. The propep-tide of von Willebrand, also named vWF antigen II (vWF:AgII), is released from platelets and endothelial cells and circulates in plasma as a glycoprotein of 100 kD. In the present study, we attempted to determine whether vWF:AgII level may provide information on the synthesis of vWF, specially in patients with von Willebrand disease (vWD). To elucidate that point, we developed an ELISA and quantify the vWF:AgII in normal individuals and in various vWD patients. The propeptide molar concentration was found to be 5nM as compared to 31 nM for mature vWF. In normal individuals, the level of vWF:AgII was significantly decreased in females from O and A blood groups. In type 2 vWD patients the level of plasma vWF:AgII appears normal in the patients with normal level of platelet vWF. In type 2 B vWD characterised by increased affinity of mature vWF for platelet glyco-protein Ib, the vWF:Ag II in contrast to the vWF antigen (vWF:Ag) was not decreased. In type 2A vWD patients the level of vWF:AgII was decreased in patients with absence of high molecular weight vWF in platelets and plasma but normal in patients with increased sensitivity to proteolysis. Finally, in type 1 vWD, some studied patients have a parallel decrease in vWF:AgII and vWF:Ag whereas in others, the vWF:Ag levels were much more affected than corresponding vWF:AgII levels, as observed in some type 2 vWD patients. Thus, in contrast to that already described, the plasma vWF:AgII level cannot discriminate type 1 from type 2 vWD patients. We conclude that the vWF:AgII measurement provides additional information on the mechanisms responsible for vWD and might also contribute to the classification of vWD patients.

 

  • References

  • 1 Ruggeri ZM, Ware J. The structure and function of von Willebrand factor.. Thromb Haemost 1992; 67: 594-9.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 2 Wagner DD, Fay PJ, Sporn LA, Sinha S, Lawrence SO. Marder et al. Divergent fates of von Willebrand factor and its propolypeptide (von Willebrand antigen II) after secretion from endothelial cells.. Proc Natl Acad Sci USA 1987; 84: 1955-9.
    CrossrefPubMedGoogle Scholar
  • 3 Wise RJ, Pittman DD, Handin RI, Kaufman RI, Orkin SH. The propeptide of von Willebrand factor independently mediates the assembly of von Willebrand multimers.. Cell 1988; 52: 229-36.
    CrossrefPubMedGoogle Scholar
  • 4 Verweij CL, Diergaarde PJ, Hart M, Pannekoek H. Full-length von Wille-brand factor (vWF) cDNA encodes a highly repetitive protein considerably larger than the mature vWF subunit.. MBO J 1986; 5: 1839-47.
    PubMedGoogle Scholar
  • 5 Takagi J, Sekiya F, Kasahara K, Inada Y, Saito Y. Inhibition of platelet-collagen interaction by propolypeptide of von Willebrand factor.. J Biol Chem 1989; 264: 6017-20.
    PubMedGoogle Scholar
  • 6 Takagi J, Kasahara K, Sekiya F, Inada Y, Saito Y. A collagen-binding glycoprotein from bovine platelets is identical to propolypeptide of von Willebrand factor.. J Biol Chem 1989; 264: 10425-30.
    PubMedGoogle Scholar
  • 7 Usui T, Fujisawa T, Takagi J, Saito Y. Propolypeptide and mature portions of von Willebrand factor of bovine origin recognize different sites on type-I collagen obtained from bovine tendon.. Eur J Biochem 1992; 205: 363-7.
    CrossrefPubMedGoogle Scholar
  • 8 Usui T, Takagi J, Saito Y. Propolypeptide of von Willebrand factor serves as a substrate for factor-XIIIa and is cross-linked to laminin.. J Biol Chem 1993; 268: 12311-6.
    PubMedGoogle Scholar
  • 9 Takagi J, Sudo Y, Saito T, Saito Y. Beta 1-Integrin-Mediated adhesion of melanoma cells to the propolypeptide of von Willebrand factor.. Eur J Biochem 1994; 222: 861-7.
    CrossrefPubMedGoogle Scholar
  • 10 Orstavik KA, Kornstad L, Reisner H, Berg K. Possible effect of secretor locus on plasma concentration of factor VIII and von Willebrand factor.. Blood 1989; 73: 990-3.
    PubMedGoogle Scholar
  • 11 Gill JC, Endes-Brooks J, Bauer PJ, Marks WJ, Montgomery RR. The effect of ABO blood group on the diagnosis of von Willebrand disease.. Blood 1987; 69: 1691-5.
    PubMedGoogle Scholar
  • 12 Sadler JE. A revised classification of von Willebrand disease. For the subcommittee on von Willebrand factor of the scientific and standardization committee of the international society on Thrombosis and Haemostasis.. Thromb Haemost 1994; 71: 520-5.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 13 Ginsburg D, Sadler JE. Von Willebrand disease: a database point mutation, insertions and deletion.. Thromb Haemost 1993; 69: 177-84.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 14 Gaucher C, Dieval J, Mazurier C. Characterization of von Willebrand factor gene defects in two unrelated patients with type IIC von Willebrand disease.. Blood 1994; 84: 1024-30.
    PubMedGoogle Scholar
  • 15 Lyons SE, Bruck ME, Bowie EJW, Ginsburg D. Impaired intracellular transport produced by a subset of type IIA von Willebrand disease mutations.. J Biol Chem 1992; 267: 4424-30.
    PubMedGoogle Scholar
  • 16 Stoddart JH, Andersen JJ, Lynch DC. Clearance of normal and type 2A von Willebrand factor in the rat.. Blood 1996; 88: 1692-9.
    PubMedGoogle Scholar
  • 17 Montgomery RR, Zimmerman TS. Von Willebrand’s disease antigen II (a new plasma and platelet antigen deficient in severe von Willebrand’s disease).. J Clin Invest 1978; 61: 1498-507.
    CrossrefPubMedGoogle Scholar
  • 18 Mc Carroll DR, Ruggeri ZM, Montgomery RR. Correlation between circulating levels of von Willebrand’s antigen II and vWF. Discrimination between type I and type II von Willebrand’s disease.. J Lab Clin Med 1984; 103: 704-11.
    PubMedGoogle Scholar
  • 19 Borchiellini A, Fijnvandrat K, Wounter ten Cate J, Pajkrt D, Van Deventer SJH, Pasterkamp G, Meijer-Huizinga F, Zwart-Huinink L, Voorberg J, Van Mourik JA. Quantitative analysis of von Willebrand factor propeptide release in vivo: effect of experimental endotoxemia and administration of 1-Deamino-8-D-Arginine vasopressin in humans.. Blood 1996; 88: 2951-8.
    PubMedGoogle Scholar
  • 20 De Romeuf C, Mazurier C. Interest of a simple and fast method for platelet von Willebrand factor characterization.. Thromb Res 1996; 83: 287-98.
    CrossrefPubMedGoogle Scholar
  • 21 Hilbert L, Gaucher C, de Romeuf C, Horellou MH, Vink T, Mazurier C. Leu 697 → Val mutation in mature von Willebrand factor is responsible for type IIB von Willebrand disease.. Blood 1994; 83: 1542-50.
    PubMedGoogle Scholar
  • 22 Mazurier C, Parquet-Gernez A, Goudemand M. Dosage de l’antigène lié au facteur VIII par la technique ELISA. Intérêt dans l’étude de la maladie de Willebrand.. Path Biol 1977; 25: 18-24.
    PubMedGoogle Scholar
  • 23 Mazurier C, Jorieux S, de Romeuf C, Samor B, Goudemand M. In vitro evaluation of a very-high-purity, solvent /detergent-treated, von Willebrand factor concentrate.. Vox Sang 1996; 61: 1-7.
    PubMedGoogle Scholar
  • 24 Vischer UM, Ingerslev J, Wolheim CB, Mestries JC, Tsakiris DA, Haefeli WE, Kruithof EKO. Acute von Willebrand factor secretion from the endothelium in vivo: Assessment through plasma propeptide (vWF:Ag II) levels.. Thromb Haemost 1997; 77: 387-93.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 25 Sodetz JM, Paulson JC, Mc Kee PA. Carbohydrate composition and identification of blood group A, B and H oligosaccharide structures on human factor VIII/von Willebrand factor.. J Biol Chem 1979; 254: 10154-60.
    PubMedGoogle Scholar
  • 26 De Romeuf C, Samor B, Mazurier C. Characterization of von Willebrand factor antigen II in a therapeutic von Willebrand factor concentrate.. Br J Haematol. 1996 93 suppl 2: Abstract 1218.
    PubMedGoogle Scholar
  • 27 De Romeuf C, Hilbert L, Gaucher C, Mazurier C. Platelet activation and aggregation induced by recombinant von Willebrand factors reproducing four type 2B von Willebrand disease missense mutations.. Thromb Haemost 1998; 79: 211-6.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 28 Francesconi M, Casonato A, Pontara E, Dallavia L, Girolani A, Deana R. Type IIB von Willebrand factor induces phospholipase A2 activation and cytosolic Ca2+ increase in platelets.. Biochemical and Biophysical Research Communication 1995; 214: 102-9.
    CrossrefPubMedGoogle Scholar
  • 29 Weiss HJ, Pietu G, Rabinowitz R, Girma JP, Rogers J, Meyer D. Heterogeneous abnormalities in the multimeric structure, antigenic properties and plasma platelet content of factor VIII/von Willebrand factor in subtypes of classic (type I) and variant (type IIA) von Willebrand’s disease.. J Lab Clin Med 1983; 101: 411-25.
    PubMedGoogle Scholar
  • 30 Mannucci PM, Lombardi R, Bader R, Vianello L, Federici AB, Solinas S, Mazzucconi MG, Mariani G. Heterogeneity of type I von Willebrand disease: Evidence for a subgroup with an abnormal von Willebrand factor.. Blood 1985; 66: 796-802.
    PubMedGoogle Scholar
  • 31 Eikenboom JCJ, Matsushita T, Reitsma PH, Tuley EA, Castaman G, Briët E, Sadler JE. Dominant type 1 von Willebrand disease caused by mutated cysteine residues in the D3 domain of von Willebrand factor.. Blood 1996; 88: 2433-41.
    PubMedGoogle Scholar
  • 32 Rodeghiero F, Castaman G, Di Bona E. Hyper-responsiveness to DDAVP for patients with type I von Willebrand’s disease and normal intra-platelet von Willebrand factor.. Eur J Haematol 1988; 40: 163-7.
    PubMedGoogle Scholar